News in brief - October 2013

Other new launches, licence changes and updates relevant to general practice.

The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment  of type II diabetes.
The licence update for Onglyza (saxagliptin) brings it in line with other DPP4 inhibitors for the treatment of type II diabetes.
  • Onglyza (saxagliptin) can now be prescribed as monotherapy in type II diabetes inadequately controlled by diet and exercise when metformin is contraindicated or not tolerated.
  • Adults with symptomatic anaemia associated with chronic renal failure being treated with Aranesp (darbepoetin alfa) may now receive once monthly dosing in the correction phase of treatment provided they are not undergoing dialysis.
  • Generic sildenafil tablets are now listed in MIMS for the treatment of erectile dysfunction.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...